SEC Stock Data Quick Answer AstroNova, Inc. reported Total Revenue of $151.28 million for fiscal year 2025. AstroNova, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $151.28M +2.2% 2024 $148.09M +3.9% 2023 $142.53M +21.3% 2022 $117.48M +1.2% 2021 $116.03M -13.0% 2020 $133.45M -2.3% 2019 $136.66M +20.5% 2018 $113.40M +15.2% 2017 $98.45M +4.0% 2016 … Read more
Quick Answer AstroNova, Inc. reported Total Revenue of $151.28 million for fiscal year 2025. AstroNova, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $151.28M+2.2% $148.09M+3.9% $142.53M+21.3% $117.48M+1.2% $116.03M-13.0% $133.45M-2.3% Revenue (ASC 606) $151.28M+2.2% $148.09M+3.9% $142.53M+21.3% $117.48M+1.2% $116.03M-13.0% $133.45M-2.3% Net Income -$14.49M-408.7% $4.69M+76.4% $2.66M-58.6% $6.43M+400.7% $1.28M-27.0% $1.76M-69.3% Diluted EPS … Read more
Quick Answer ALNYLAM PHARMACEUTICALS, INC. reported Shares Outstanding of 132.38 million shares for fiscal year 2025. ALNYLAM PHARMACEUTICALS, INC. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 132.38M +2.4% 2024 129.29M +2.8% 2023 125.79M +1.5% 2022 123.92M +3.1% 2021 120.18M +3.2% 2020 116.43M +3.8% 2019 112.19M +10.9% 2018 101.18M +1.5% 2017 … Read more
Quick Answer ALNYLAM PHARMACEUTICALS, INC. reported Operating Income of $501.58 million for fiscal year 2025. ALNYLAM PHARMACEUTICALS, INC. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 $501.58M +383.6% 2024 -$176.88M +37.3% 2023 -$282.18M +64.1% 2022 -$785.07M -10.8% 2021 -$708.65M +14.5% 2020 -$828.44M +11.8% 2019 -$939.43M -15.3% 2018 -$814.67M -62.9% 2017 -$500.09M … Read more
Quick Answer ALNYLAM PHARMACEUTICALS, INC. reported R&D Expense of $1.32 billion for fiscal year 2025. ALNYLAM PHARMACEUTICALS, INC. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $1.32B +17.2% 2024 $1.13B +12.1% 2023 $1.00B +13.7% 2022 $883.01M +11.5% 2021 $792.16M +21.0% 2020 $654.82M -0.0% 2019 $655.11M +29.6% 2018 $505.42M +29.4% 2017 $390.63M … Read more
Quick Answer ALNYLAM PHARMACEUTICALS, INC. reported Stockholders Equity of $789.18 million for fiscal year 2025. ALNYLAM PHARMACEUTICALS, INC. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $789.18M +1076.3% 2024 $67.09M +130.4% 2023 -$220.64M -39.5% 2022 -$158.22M -126.9% 2021 $588.20M -42.1% 2020 $1.02B -29.4% 2019 $1.44B +10.5% 2018 $1.30B -26.3% 2017 $1.77B … Read more
Quick Answer ALNYLAM PHARMACEUTICALS, INC. reported Cash and Equivalents of $1.66 billion for fiscal year 2025. ALNYLAM PHARMACEUTICALS, INC. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $1.66B +71.5% 2024 $966.43M +18.9% 2023 $812.69M -6.2% 2022 $866.39M +5.7% 2021 $819.98M +65.1% 2020 $496.58M -9.2% 2019 $547.18M +30.2% 2018 $420.15M … Read more
Quick Answer ALNYLAM PHARMACEUTICALS, INC. reported Total Assets of $4.97 billion for fiscal year 2025. ALNYLAM PHARMACEUTICALS, INC. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $4.97B +17.1% 2024 $4.24B +10.7% 2023 $3.83B +8.0% 2022 $3.55B -2.7% 2021 $3.64B +6.9% 2020 $3.41B +42.2% 2019 $2.40B +52.1% 2018 $1.57B -21.1% 2017 $1.99B … Read more
Quick Answer ALNYLAM PHARMACEUTICALS, INC. reported Diluted EPS of $2.33 per share for fiscal year 2025. ALNYLAM PHARMACEUTICALS, INC. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 $2.33 +206.9% 2024 -$2.18 +38.1% 2023 -$3.52 +62.2% 2022 -$9.30 -29.2% 2021 -$7.20 +3.5% 2020 -$7.46 +8.0% 2019 -$8.11 — Quarterly Diluted EPS Quarter … Read more
Quick Answer ALNYLAM PHARMACEUTICALS, INC. reported Net Income of $313.75 million for fiscal year 2025. ALNYLAM PHARMACEUTICALS, INC. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 $313.75M +212.8% 2024 -$278.16M +36.8% 2023 -$440.24M +61.1% 2022 -$1.13B -32.6% 2021 -$852.82M +0.6% 2020 -$858.28M +3.1% 2019 -$886.12M -16.4% 2018 -$761.50M -55.1% 2017 -$490.87M … Read more